Review



oseltamivir acid  (TargetMol)


Bioz Verified Symbol TargetMol is a verified supplier
Bioz Manufacturer Symbol TargetMol manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    TargetMol oseltamivir acid
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Acid, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Oseltamivir/pmc13198263-265-16-24
    Average 97 stars, based on 5 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    97/100 stars

    Images

    1) Product Images from "A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1"

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1

    Journal: Acta Pharmaceutica Sinica. B

    doi: 10.1016/j.apsb.2026.02.003

    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or oseltamivir phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Figure Legend Snippet: The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or oseltamivir phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).

    Techniques Used: Infection, Analysis, Isolation, Virus, Real-time Polymerase Chain Reaction, Western Blot, Quantitative Proteomics, Staining, H&E Stain

    Compound H1N1-17 showed synergistic effect with oseltamivir acid against H1N1. (A) The three-dimensional (3-D) dose-response surface of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid. The dose-response surface exhibited a convex shape resembling a flipping sail, especially at an inhibition level of 40%–60% (green). According to the principle of Loewe additivity, the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid was synergistic. (B) The two-dimensional isobologram of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid at the inhibition effect of 50%. By controlling the concentrations of compound H1N1-17 and oseltamivir acid as a constant separately, the EC 50 against H1N1 of another compound could be calculated to obtain a series of data points, and then the cross-sectional curve in the 3-D dose-response surface at the inhibition level of 50% was obtained, which presented a concave upward curve. According to the principle of Loewe additivity, compound H1N1-17 showed a synergistic effect with oseltamivir acid against H1N1.
    Figure Legend Snippet: Compound H1N1-17 showed synergistic effect with oseltamivir acid against H1N1. (A) The three-dimensional (3-D) dose-response surface of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid. The dose-response surface exhibited a convex shape resembling a flipping sail, especially at an inhibition level of 40%–60% (green). According to the principle of Loewe additivity, the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid was synergistic. (B) The two-dimensional isobologram of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid at the inhibition effect of 50%. By controlling the concentrations of compound H1N1-17 and oseltamivir acid as a constant separately, the EC 50 against H1N1 of another compound could be calculated to obtain a series of data points, and then the cross-sectional curve in the 3-D dose-response surface at the inhibition level of 50% was obtained, which presented a concave upward curve. According to the principle of Loewe additivity, compound H1N1-17 showed a synergistic effect with oseltamivir acid against H1N1.

    Techniques Used: Inhibition

    Combination index (CI) of compound H1N1-17 and  oseltamivir acid  at 50% inhibition.
    Figure Legend Snippet: Combination index (CI) of compound H1N1-17 and oseltamivir acid at 50% inhibition.

    Techniques Used: Inhibition

    Related Articles

    Infection:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Analysis:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Isolation:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Virus:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Real-time Polymerase Chain Reaction:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Western Blot:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Quantitative Proteomics:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Staining:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    H&E Stain:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).

    Inhibition:

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1
    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Article Title: PA-E18G substitution in influenza A virus confers resistance to ZX-7101, a cap-dependent endonuclease inhibitor.
    Article Snippet: Oseltamivir acid purchased from TargetMol Chemicals Inc. (Shanghai, China).



    Similar Products

    95
    MedChemExpress oseltamivir acid
    Oseltamivir Acid, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pm42243334-79-14-22
    Average 95 stars, based on 1 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    97
    TargetMol oseltamivir acid
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Acid, supplied by TargetMol, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Oseltamivir/pmc13198263-265-16-24
    Average 97 stars, based on 1 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    95
    MedChemExpress oseltamivir carboxylate
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Carboxylate, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pm41989160-353-3-6
    Average 95 stars, based on 1 article reviews
    oseltamivir carboxylate - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    90
    Biosynth Carbosynth oseltamivir acid
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Acid, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/us12594285-1001-0-2
    Average 90 stars, based on 1 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    86
    Shanghai Macklin Biochemical oseltamivir acid
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Acid, supplied by Shanghai Macklin Biochemical, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/acid+oseltamivir/pm41871821-157-0-5
    Average 86 stars, based on 1 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    97
    Gilead Sciences hand sialic acid analogs neuraminidase inhibitors
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Hand Sialic Acid Analogs Neuraminidase Inhibitors, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/Tamiflu/10__59957_slash_jctm__v61__i1__2026__6-36-33-40
    Average 97 stars, based on 1 article reviews
    hand sialic acid analogs neuraminidase inhibitors - by Bioz Stars, 2026-11
    97/100 stars
      Buy from Supplier

    86
    Shanghai Yuanye Biochemicals oseltamivir acid
    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or <t>oseltamivir</t> phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).
    Oseltamivir Acid, supplied by Shanghai Yuanye Biochemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/oseltamivir+acid/acid+oseltamivir/pm41422652-49-76-81
    Average 86 stars, based on 1 article reviews
    oseltamivir acid - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    Image Search Results


    The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or oseltamivir phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1

    doi: 10.1016/j.apsb.2026.02.003

    Figure Lengend Snippet: The effect of compound H1N1-17 on mice challenged with lethal H1N1 (A/PR/8/34). Six mice in each group were intranasally inoculated with MLD 100 of H1N1 (A/PR/8/34) and treated with compound H1N1-17 at 25 mg/kg/day intraperitoneally or oseltamivir phosphate at 25 mg/kg/day intragastrically from −1 to 10 days post infection (dpi). Survival and body weight were monitored daily from −1 to 21 dpi. For pathological analysis, another parallel experiment was performed. Three mice in each group were euthanized on 10 dpi, and lung tissues were isolated. (A) Survival and body weight of H1N1-infected and drug-treated mice. Compound H1N1-17 effectively protected H1N1-infected mice from death and weight loss. Values are means ± SD ( n = 6). (B) Compound H1N1-17 significantly reduced H1N1 in mice lung tissues. Virus titers in lung tissues were detected by one-step real time PCR assay at 10 dpi. LLOQ, lower limit of quantification: 10 3 copies/mL. Values are means ± SD ( n = 3). (C) Viral proteins in lung tissues were detected by Western blot assay at 10 dpi. Relative quantification was shown on the right ( n = 3). Values are means ± SD. (D) Compound H1N1-17 effectively alleviated lung injury caused by viral infection. H1N1-induced pathogenesis was determined by H&E staining at 10 dpi. Smith lung injury score was shown on the right. Values are means ± SD ( n = 3). ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001, by two-way Anova (or mixed model) in (C) and one-way Anova (and nonparametric or mixed) in (B) and (D).

    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Techniques: Infection, Analysis, Isolation, Virus, Real-time Polymerase Chain Reaction, Western Blot, Quantitative Proteomics, Staining, H&E Stain

    Compound H1N1-17 showed synergistic effect with oseltamivir acid against H1N1. (A) The three-dimensional (3-D) dose-response surface of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid. The dose-response surface exhibited a convex shape resembling a flipping sail, especially at an inhibition level of 40%–60% (green). According to the principle of Loewe additivity, the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid was synergistic. (B) The two-dimensional isobologram of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid at the inhibition effect of 50%. By controlling the concentrations of compound H1N1-17 and oseltamivir acid as a constant separately, the EC 50 against H1N1 of another compound could be calculated to obtain a series of data points, and then the cross-sectional curve in the 3-D dose-response surface at the inhibition level of 50% was obtained, which presented a concave upward curve. According to the principle of Loewe additivity, compound H1N1-17 showed a synergistic effect with oseltamivir acid against H1N1.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1

    doi: 10.1016/j.apsb.2026.02.003

    Figure Lengend Snippet: Compound H1N1-17 showed synergistic effect with oseltamivir acid against H1N1. (A) The three-dimensional (3-D) dose-response surface of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid. The dose-response surface exhibited a convex shape resembling a flipping sail, especially at an inhibition level of 40%–60% (green). According to the principle of Loewe additivity, the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid was synergistic. (B) The two-dimensional isobologram of the combination therapy against H1N1 of compound H1N1-17 and oseltamivir acid at the inhibition effect of 50%. By controlling the concentrations of compound H1N1-17 and oseltamivir acid as a constant separately, the EC 50 against H1N1 of another compound could be calculated to obtain a series of data points, and then the cross-sectional curve in the 3-D dose-response surface at the inhibition level of 50% was obtained, which presented a concave upward curve. According to the principle of Loewe additivity, compound H1N1-17 showed a synergistic effect with oseltamivir acid against H1N1.

    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Techniques: Inhibition

    Combination index (CI) of compound H1N1-17 and  oseltamivir acid  at 50% inhibition.

    Journal: Acta Pharmaceutica Sinica. B

    Article Title: A novel entry inhibitor targeting the stalk domain of the hemagglutinin of H1N1

    doi: 10.1016/j.apsb.2026.02.003

    Figure Lengend Snippet: Combination index (CI) of compound H1N1-17 and oseltamivir acid at 50% inhibition.

    Article Snippet: The compound pimodivir (CAS: 1629869-44-8), favipiravir (CAS: 259793-96-9), zanamivir (CAS: 139110-80-8), oseltamivir phosphate (CAS: 204255-11-8) and oseltamivir acid (CAS: 187227-45-8) were all purchased from Topscience Co. Ltd. (Shanghai, China).

    Techniques: Inhibition